Advancements in anemias related to chronic conditions

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 9, 2010, Pages 1217-1226

  Guidi, Gian Cesare ^a   Lechi Santonastaso, Clara ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

anemia; anemia of chronic disease; chronic kidney disease; erythropoietin; hepcidin; iron metabolism

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRITIN; FERROPORTIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 1; INTERLEUKIN 6; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; VASOPRESSIN;

ANEMIA; ANEMIA OF CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ERYTHROCYTE; ERYTHROPHAGOCYTOSIS; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HEART FAILURE; HEMATOCRIT; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; LYSOSOME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SOLID TUMOR; TRANSFERRIN BLOOD LEVEL;

ANEMIA; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CHRONIC DISEASE; HOMEOSTASIS; HUMANS; IRON; KIDNEY DISEASES;

EID: 77957372336     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.264     Document Type: Review

References (82)

1. Zwart A, van Assendelft OW, Bull BS, England JM, Lewis SM, Zijlstra WG. ICSH recommendations for reference method for hemoglobinometry in human blood (ICSH standards 1995) and specifications for international hemoglobincyanamyde standard. J Clin Pathol 1996;49:271-4. (Pubitemid 26141736)
2. Bull BS, Rittenbach JD. A proposed reference haematocrit derived from multiple MCHC determinations via hemoglobin measurements. Clin Lab Haematol 1990;12(Suppl. 1):43-53.
3. Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance sports: a feasibility study. Haematologica 2003;88:570-81. (Pubitemid 36648447)
4. Brugnara C, Schiller B, Moran J. Reticulocyte haemoglobin equivalent (Ret-He) and assessment of iron-deficient states. Clin Lab Haem 2006;28:303-30. (Pubitemid 44453675)
5. Urrechaga E. Clinical utility of the new Beckman-Coulter parameter red blood cell size factor in the study of erithropoiesis. Int J Lab Hem 2009;31:623-9.
6. Sandberg S, Rustad P, Johannesen B, Stølsnes B. Within-subject biological variation of reticulocytes and reticulocytederived parameters. Eur J Haematol 1998;61:42-8. (Pubitemid 28326402)
7. Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hem 2009;31:277-97.
8. Raya G, Henny J, Steinmetz J, Herbeth B, Siest G. Soluble transferrin receptor (sTfR): biological variations and reference limits. Clin Chem Lab Med 2001;39:1162-8. (Pubitemid 33133636)
9. Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, et al. Pre-analytical and biological variability in circulating interleukin-6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2007;13:59-78.
10. Blanc B, Finch CA, Hallberg L, Herbert V, Lawkowicz W, Layrisse M, et al. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 1968;405:1-40.
11. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682-93.
12. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23. (Pubitemid 40349504)
13. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002;16:87-96. (Pubitemid 34742225)
14. Groopman JE, Itri LM. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
15. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes. Insights from a cohort of 12.065 patients with new-onset heart failure. Circulation 2003;107:223-5.
16. Al Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-62. (Pubitemid 32912694)
17. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36. (Pubitemid 34700619)
18. Similowski T, Agusti A, MacNee W, Schonhofer B. The potential impact of anemia of chronic disease in COPD. Eur Respir J 2006;27:390-6. (Pubitemid 43180920)
19. Muñoz M, Villar I, García-Erce JA. An update on iron physiology. World J Gastroenterol 2009;15:4617-26.
20. Means RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003;2:116-21.
21. Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010;24:39-47.
22. Broudy VC. Stem cell factor. Blood 1997;90:1345-53.
23. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990;63:185-94. (Pubitemid 20359516)
24. Donovan A, Roy CN, Andrews NC. The ins and outs of iron homeostasis. Physiology 2006;21:115-23. (Pubitemid 43752507)
25. Laftah AH, Sharma N, Brookes MJ, McKie AT, Simpson RJ, Tariq H, et al. Tumour necrosis factor α causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J 2006;397:61-7. (Pubitemid 44032837)
26. Graziadei I, Gaggl S, Kaserbacher R, Braunsteiner H, Vogel W. The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burstforming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake, Blood 1994;83:260-8. (Pubitemid 2020747)
27. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92. (Pubitemid 20231525)
28. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996;87:4824-30. (Pubitemid 26162385)
29. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-8. (Pubitemid 37194211)
30. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-7. (Pubitemid 27121300)
31. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86.
32. De Domenico I, McVey Ward D, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007;18:2569-78. (Pubitemid 47025722)
33. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117:285-97.
34. Stuart KA, Anderson J, Frazer DM, Powell LW, McCullen M, Fletcher LM, et al. Duodenal expression of iron transport molecules in untreated haemochromatosis subjects. Gut 2003;52:953-9. (Pubitemid 36765285)
35. Anderson GJ. Mechanism of iron loading and toxicity. Am J Hematol 2007;82:1128-32.
36. Anderson GJ, Frazer DM, McLaren D. Iron absorption and metabolism. Curr Opin Gastroen 2009;25:129-35.
37. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309. (Pubitemid 30628088)
38. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191-200. (Pubitemid 43960600)
39. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999;21:195-9. (Pubitemid 29070366)
40. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 2006;290: G199-203.
41. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3. (Pubitemid 40007660)
42. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab 2005;1:155-7. (Pubitemid 43960605)
43. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328-33. (Pubitemid 43053559)
44. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6. (Pubitemid 39069926)
45. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-44.
46. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006;108:3730-5. (Pubitemid 44864551)
47. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005;106:2196-9. (Pubitemid 41291740)
48. Chung B, Chaston T, Marks J, Srai SK, Sharp PA. Hepcidin decreases iron transporter expression in vivo in mouse duodenum and spleen and in vitro in THP-1 macrophages and intestinal Caco-2 cells. J Nutr 2009;139:1457-62.
49. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003;33:21-2. (Pubitemid 36068676)
50. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol 2006;81:202-9. (Pubitemid 43297263)
51. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 2007;53:620-8. (Pubitemid 46580231)
52. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica 2008;93:90-7. (Pubitemid 351156156)
53. Piperno A, Mariani R, Trombini P, Girelli D. Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol 2009;15:538-51.
54. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009;94:1748-52.
55. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007;110:1048-54. (Pubitemid 47267447)
56. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004;66:1310-4. (Pubitemid 39302630)
57. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002;80:35-8. (Pubitemid 34534156)
58. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004;65:757-67. (Pubitemid 38251052)
59. Strippoli GF, Manno C, Schena FP, Craig JC. Haemoglobin and haematocrit targets for the anemia of chronic renal disease. Cochrane Database Syst Rev 2006; (4):003967.
60. Besarab A, Kline Bolton W, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
61. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al., for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98. (Pubitemid 44749317)
62. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al., TREAT Investigators. Baseline characteristics in the trial to reduce cardiovascular events with aranesp therapy (TREAT). Am J Kidney Dis 2009;54:59-69.
63. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al., the TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
64. Gilbertson DT, Peng Y, Bradbury B, Ebben JP, Collins AJ. Hemoglobin level variability: anemia management among variability groups. Am J Nephrol 2009;30:491-8.
65. Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005;45:136-47. (Pubitemid 40038054)
66. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006;26:261-8. (Pubitemid 44722454)
67. Eckardt KU. Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease. Nephron 1994;67:7-23.
68. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis bind to the human erythropoietin gene enhancer at a site required for trascriptional activation. Mol Cell Biol 1992;12:5447-54.
69. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-14.
70. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
71. Nangaku M, Eckardt KU. Hypoxia and the HIF system in kidney disease. J Mol Med 2007;85:1325-30. (Pubitemid 50004091)
72. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygenregulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997;272:20055-62. (Pubitemid 27340110)
73. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-32. (Pubitemid 47036326)
74. Hamada Y, Fukagawa M. Is hepcidin the star player in iron metabolism in chronic kidney disease? Kidney Int 2009;75:873-4.
75. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-81.
76. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505-8.
77. Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ, et al. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood 2009;25; 113:6707-15.
78. Tanaka T, Miyata T, Inagi R, Kurokawa K, Adler S, Fujita T, et al. Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. Kidney Int 2003;64:2020-32. (Pubitemid 37449536)
79. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004;65:871-80. (Pubitemid 38251062)
80. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351-66.
81. Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K, et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008;295: F1023-9.
82. Erwig LP. Macrophages and hypoxia in human chronic kidney disease. Kidney Int 2008;74:405-6.